Literature DB >> 21117603

Spectral domain optical coherence tomography imaging of dry age-related macular degeneration.

Zohar Yehoshua1, Philip J Rosenfeld, Giovanni Gregori, Fernando Penha.   

Abstract

Spectral domain optical coherence tomography is a useful new technology for imaging and measuring geographic atrophy (GA) and drusen, the hallmarks of dry age-related macular degeneration (AMD). The advantage of using this novel technique over other imaging modalities for dry AMD is that the same scan pattern can be used to image both drusen and GA while obtaining reproducible, quantitative data on both the area of GA and the morphologic features of drusen. Moreover, this strategy enables the clinician to follow the disease as it progresses from drusen to both GA and choroidal neovascularization. No other imaging modality is able to quantitatively assess all forms of AMD. This unique feature of spectral domain optical coherence tomography makes it the ideal imaging modality for clinical trials designed to assess new drugs for the treatment of dry AMD. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Year:  2010        PMID: 21117603     DOI: 10.3928/15428877-20101031-19

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  12 in total

1.  Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2).

Authors:  Ronald P Danis; Amitha Domalpally; Emily Y Chew; Traci E Clemons; Jane Armstrong; John Paul SanGiovanni; Frederick L Ferris
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-08       Impact factor: 4.799

2.  Drusen and RPE atrophy automated quantification by optical coherence tomography in an elderly population.

Authors:  B Diniz; D C Rodger; V R Chavali; T MacKay; S Y Lee; D Stambolian; S V R Sadda
Journal:  Eye (Lond)       Date:  2014-11-07       Impact factor: 3.775

3.  Effect of change in drusen evolution on photoreceptor inner segment/outer segment junction.

Authors:  Kathrin I Hartmann; Maria L Gomez; Dirk-Uwe G Bartsch; Alexander K Schuster; William R Freeman
Journal:  Retina       Date:  2012-09       Impact factor: 4.256

4.  Volumetric directional optical coherence tomography.

Authors:  Shuibin Ni; Shanjida Khan; Thanh-Tin P Nguyen; Ringo Ng; Brandon J Lujan; Ou Tan; David Huang; Yifan Jian
Journal:  Biomed Opt Express       Date:  2022-01-21       Impact factor: 3.732

5.  Predicting visual outcomes for macular disease using optical coherence tomography.

Authors:  Pearse A Keane; Srinivas R Sadda
Journal:  Saudi J Ophthalmol       Date:  2011-01-26

6.  Serum cytokines as biomarkers for age-related macular degeneration.

Authors:  Khaled Nassar; Salvatore Grisanti; Elshaymaa Elfar; Julia Lüke; Matthias Lüke; Swaantje Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-24       Impact factor: 3.117

7.  Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration.

Authors:  Sijia Cao; Ashley Ko; Marita Partanen; Kaivon Pakzad-Vaezi; Andrew B Merkur; David A Albiani; Andrew W Kirker; Aikun Wang; Jing Z Cui; Farzin Forooghian; Joanne A Matsubara
Journal:  Am J Ophthalmol       Date:  2013-09-29       Impact factor: 5.258

8.  Automatic montage of SD-OCT data sets.

Authors:  Ying Li; Giovanni Gregori; Byron L Lam; Philip J Rosenfeld
Journal:  Opt Express       Date:  2011-12-19       Impact factor: 3.894

9.  Association of OCT derived drusen measurements with AMD associated-genotypic SNPs in Amish population.

Authors:  Venkata Ramana Murthy Chavali; Bruno Diniz; Jiayan Huang; Gui-Shuang Ying; SriniVas R Sadda; Dwight Stambolian
Journal:  J Clin Med       Date:  2015       Impact factor: 4.241

Review 10.  The potential of spectral domain optical coherence tomography imaging based retinal biomarkers.

Authors:  Prateep Phadikar; Sandeep Saxena; Surabhi Ruia; Timothy Y Y Lai; Carsten H Meyer; Dean Eliott
Journal:  Int J Retina Vitreous       Date:  2017-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.